Panacea Biotec’s arm launches Paclitaxel Protein-Bound Particles for Injectable Suspension

28 Oct 2023 Evaluate

Panacea Biotec’s material wholly owned subsidiary -- Panacea Biotec Pharma through its strategic partner Apotex Inc., Canada has launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane in the Canadian market.

Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and adenocarcinoma of the pancreas. ABRAXANE is a registered trademark of Abraxis BioScience, LLC, which is a wholly owned subsidiary of Bristol- Myers Squibb Company. This is the first generic launch of Abraxane in Canada and provides patients with a high quality medication at an affordable price. The current market size of Abraxane in Canada is $26.4 million.

Panacea Biotec had an existing collaboration agreement with Apotex Inc. for research, development, license, supply and sale of the said Product in US, Canada, Australia & New Zealand. Pursuant to the said collaboration agreement Panacea Biotec had undertaken research, development and manufacturing of the product at its stateof-the art pharmaceutical formulations facility at Baddi, Himachal Pradesh and Apotex Inc. will undertake the marketing, sales and distribution thereof in the Canadian market.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.


Panacea Biotec Share Price

344.65 -0.10 (-0.03%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×